Fucosylated lipid nanocarriers loaded with antibiotics efficiently inhibit mycobacterial propagation in human myeloid cells.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Monteiro, João T
MetadataShow full item record
AbstractAntibiotic treatment of tuberculosis (TB) is complex, lengthy, and can be associated with various adverse effects. As a result, patient compliance often is poor, thus further enhancing the risk of selecting multi-drug resistant bacteria. Macrophage mannose receptor (MMR)-positive alveolar macrophages (AM) constitute a niche in which Mycobacterium tuberculosis replicates and survives. Therefore, we encapsulated levofloxacin in lipid nanocarriers functionalized with fucosyl residues that interact with the MMR. Indeed, such nanocarriers preferentially targeted MMR-positive myeloid cells, and in particular, AM. Intracellularly, fucosylated lipid nanocarriers favorably delivered their payload into endosomal compartments, where mycobacteria reside. In an in vitro setting using infected human primary macrophages as well as dendritic cells, the encapsulated antibiotic cleared the pathogen more efficiently than free levofloxacin. In conclusion, our results point towards carbohydrate-functionalized nanocarriers as a promising tool for improving TB treatment by targeted delivery of antibiotics.
CitationJ Control Release. 2021 Jun 10;334:201-212. doi: 10.1016/j.jconrel.2021.04.012. Epub 2021 Apr 16.
AffiliationTWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.;HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.
The following license files are associated with this item:
- Creative Commons
- The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection.
- Authors: Giraud-Gatineau A, Coya JM, Maure A, Biton A, Thomson M, Bernard EM, Marrec J, Gutierrez MG, Larrouy-Maumus G, Brosch R, Gicquel B, Tailleux L
- Issue date: 2020 May 4
- [Prospects for development of new antituberculous drugs].
- Authors: Tomioka H
- Issue date: 2002 Aug
- Mannosylated graphene oxide as macrophage-targeted delivery system for enhanced intracellular M.tuberculosis killing efficiency.
- Authors: Pi J, Shen L, Shen H, Yang E, Wang W, Wang R, Huang D, Lee BS, Hu C, Chen C, Jin H, Cai J, Zeng G, Chen ZW
- Issue date: 2019 Oct
- [Development of antituberculous drugs: current status and future prospects].
- Authors: Tomioka H, Namba K
- Issue date: 2006 Dec
- Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection.
- Authors: Dwivedi VP, Bhattacharya D, Singh M, Bhaskar A, Kumar S, Fatima S, Sobia P, Kaer LV, Das G
- Issue date: 2019 Oct 28